CMS Phasing Out Medicaid Workforce Initiatives
On July 11, CMS notified states that, going forward, it does not anticipate approving new…
CMS Phasing Out Medicaid Workforce Initiatives
On July 11, CMS notified states that, going forward, it does not anticipate approving new 1115 demonstration workforce initiatives or extending existing waivers. Such changes may limit states’ abilities to pursue initiatives investing in the Medicaid workforce,
FTC Has Long Said Products Must Back Up Health Claims. A MAHA Lawsuit Would Upend That.
Don’t get Nathan Jones started on xylitol, the active ingredient in his chewing gum, nasal spray, and other products. He’ll talk your ear off about its wondrous powers against tooth decay, as well as its potential to fight covid, heart disease, Alzheimer’s — you name it. For now, Jones, the founder of Xlear, can’t make…
As Measles Exploded, Officials in Texas Looked to CDC Scientists. Under Trump, No One Answered.
As measles surged in Texas early this year, the Trump administration’s actions sowed fear and confusion among CDC scientists that kept them from performing the agency’s most critical function — emergency response — when it mattered most, an investigation from KFF Health News shows. The outbreak soon became the worst the United States has endured…
Rosemarie Day & Me invite you to see Atul Gawande
My friend Rosemarie Day joins me to talk about the Healthcare Leaders for Democracy session coming up on September 4 (Thursday) at 8pm ET 5pm PT. It’s a one hour session with Atul Gawande as the keynote speaker, joined by Don Berwick and John McDonough. It’ll be a fascinating discussion and it’s a fundraiser for…
First Therapy for Rare Tumor Is a Blockbuster Prospect, But Does Precigen Have the Cash to Make It Happen?
Precigen’s Papzimeos is the first FDA-approved drug for the rare disease recurrent respiratory papillomatosis, or RRP. While this immunotherapy carries blockbuster expectations, Precigen’s financial reports indicate budgetary challenges. The post First Therapy for Rare Tumor Is a Blockbuster Prospect, But Does Precigen Have the Cash to Make It Happen? appeared first on MedCity News.
Insurers are Pulling Back on MA. How Does this Affect Patients?
Many insurers seem to be retreating from Medicare Advantage by exiting unprofitable markets and reducing benefits. This could be extremely disruptive to patients, experts warn. The post Insurers are Pulling Back on MA. How Does this Affect Patients? appeared first on MedCity News.
AI Meets Care Transitions: How One Startup Is Seeking to Reduce Readmissions and Costs
Boston-based startup Cascala Health raised an $8.6 million seed round to expand its AI platform for risk-bearing providers. The platform is designed to make patient care transitions safer and more efficient, as well as to help care teams spot risks earlier. The post AI Meets Care Transitions: How One Startup Is Seeking to Reduce Readmissions…
After Wegovy’s Historic MASH Approval, What’s Next?
Approval is only the beginning. Now comes the harder part: identifying the right patients, detecting the disease earlier, and monitoring outcomes so that this promising treatment is effective at scale. The post After Wegovy’s Historic MASH Approval, What’s Next? appeared first on MedCity News.
Secretary Kennedy’s Pride and Prejudice
His longstanding anti-vaccine rhetoric and vocal opposition to science-backed expert consensus has caused widespread concern among public health and medical professionals about the appropriateness of his leadership. The post Secretary Kennedy’s Pride and Prejudice appeared first on MedCity News.
Develop Health Secures $14.3M to Streamline Prior Authorization
Develop Health’s Series A funding round was led by Wing Venture Capital, and included participation from Afore Capital, J Ventures and South Park Commons. The post Develop Health Secures $14.3M to Streamline Prior Authorization appeared first on MedCity News.
